The Corporate Liaison Board of The Endocrine Society serves as a forum for communication between The Endocrine Society, The Hormone Foundation and the pharmaceutical and biotechnology industry in endocrinology. As such, the Board:

• Promotes reciprocal access to the business, medical and scientific leadership of the respective organizations;
• Integrates industry trends and needs with strategic objectives of the Society and The Hormone Foundation;
• Fosters partnerships and collaborations between the Society, The Hormone Foundation and industry involving projects and services of common interest;
• Recognizes the scientific and professional contributions of Society members who work in industry.

Approved by CLB Planning Group on November 20, 1998 Approved by The Endocrine Society Council on January 9, 1999 Approved Revision by The Endocrine Society Council on June, 2004

Learn more information about the goals of the Corporate Liaison Board.

CORPORATE LIAISON BOARD MEMBERS

Abbott Laboratories
Amgen
AstraZeneca
Beckman Coulter, Inc.
Boehringer Ingelheim Pharmaceuticals, Inc.
Genentech, Inc.
Genzyme Corporation
GlaxoSmithKline Pharmaceuticals
Lilly USA, LLC
Medtronic Diabetes
Merck
Novartis Pharmaceuticals Corporation
Novo Nordisk Inc.
Pfizer, Inc.
Quest Diagnostics
Sanofi-Aventis Pharmaceuticals
Solvay Pharmaceuticals, Inc.
Takeda Pharmaceuticals North America, Inc.
Wyeth Pharmaceuticals